Ciloxan® Ointment
ciprofloxacin 0.3% · ophthalmic ointment
Antibiotic
Approved uses
Bacterial conjunctivitis
1/2 inch ribbon in the conjunctival sac TID x 2 days, then 1/2 inch ribbon BID x 5 days.
OFF-LABELNot in the FDA label for this product
Bacterial keratitis
Trial regimen: every 1 to 2 hours for 2 days, then every 4 hours for 12 days. Ribbon length was not reported.
Nonrandomized · n=253
Prospective multicenter study with a nonrandomized concurrent comparison, 253 treated and 145 culture-positive evaluable: clinical success with initial treatment in 93% (135 of 145) versus 70% (28 of 40) among eligible culture-positive patients not enrolled and given conventional therapy. A transient white crystalline corneal precipitate occurred in 13% (32 of 253), shown by liquid chromatography in two cases to be the drug. PubMed indexes this as a clinical trial and comparative study, not a randomized controlled trial, so the comparison group is not a randomized control arm.
Contraindications
- A history of hypersensitivity to ciprofloxacin or any other component of the medication
- A history of hypersensitivity to other quinolones may also contraindicate use
Ophthalmic ointment, 3.5 g tube, 0.3% (3 mg ciprofloxacin base per gram)
Fluoroquinolone; bactericidal through interference with DNA gyrase, the enzyme needed for synthesis of bacterial DNA. In vitro resistance usually develops slowly by multiple-step mutation, and ciprofloxacin does not cross-react with beta-lactams or aminoglycosides, so organisms resistant to those agents may be susceptible to ciprofloxacin.
Warnings & Precautions
- Topical ophthalmic use only: Not for injection into the eye.
- Hypersensitivity (anaphylactic) reactions: Serious and occasionally fatal reactions, some following the first dose, have been reported with systemic quinolone therapy; some were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching; only a few patients had a history of hypersensitivity reactions.
- Serious anaphylactic reactions: These require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated.
- Corneal healing delay: Ophthalmic ointments may retard corneal healing and cause visual blurring.
- Nonsusceptible organism overgrowth: Prolonged use may allow overgrowth of nonsusceptible organisms including fungi; start appropriate therapy if superinfection occurs.
- Hypersensitivity rash: Discontinue at the first appearance of a skin rash or any other sign of hypersensitivity reaction.
- Examination with magnification: Whenever clinical judgment dictates, examine the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Drug interactions: Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin; systemic administration of some quinolones has been shown to elevate plasma theophylline, interfere with caffeine metabolism, and enhance the effects of warfarin and its derivatives, and has been associated with transient serum creatinine elevations with cyclosporine.
- Corneal precipitate risk: In a prospective case series of patients with bacterial keratitis, an off-label use for this ointment, which the label indicates only for bacterial conjunctivitis, the ointment was instilled every 1 to 2 hours for 2 days, then every 4 hours for 12 days; no serious adverse event attributable to ciprofloxacin ointment occurred, although 32 (13%) of 253 patients developed a transient white crystalline corneal precipitate.
- Contact lens wear: Not appropriate while signs and symptoms of bacterial conjunctivitis are present.
- Contamination: Do not touch tip to any surface as this may contaminate the ointment; do not use the product if the imprinted carton seals have been damaged or removed.
Common Side Effects
Discomfort and keratopathy were reported in 2% of patients in clinical studies. Other reactions occurring in less than 1% of patients included allergic reactions, blurred vision, corneal staining, decreased visual acuity, dry eye, edema, epitheliopathy, eye pain, foreign body sensation, hyperemia, irritation, keratoconjunctivitis, lid erythema, lid margin hyperemia, photophobia, pruritus, and tearing. Systemic reactions occurred at an incidence below 1% and included dermatitis, nausea, and taste perversion.
Pregnancy: Reproduction studies in rats and mice at up to six times the usual daily human oral dose showed no impaired fertility and no fetal harm; oral dosing in rabbits at 30 and 100 mg/kg caused gastrointestinal disturbance, maternal weight loss and increased abortion without teratogenicity, and intravenous dosing up to 20 mg/kg produced no maternal toxicity, embryotoxicity or teratogenicity. No adequate and well controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk.
Lactation: Excretion of topically applied drug in human milk is unknown; oral dosing is excreted in the milk of lactating rats and has been reported in human breast milk after a single 500 mg dose; caution should be exercised when the ointment is given to a nursing mother.
Safety and effectiveness not established below age 2.